LU90458I2 - Refacto - Google Patents

Refacto

Info

Publication number
LU90458I2
LU90458I2 LU90458C LU90458C LU90458I2 LU 90458 I2 LU90458 I2 LU 90458I2 LU 90458 C LU90458 C LU 90458C LU 90458 C LU90458 C LU 90458C LU 90458 I2 LU90458 I2 LU 90458I2
Authority
LU
Luxembourg
Prior art keywords
pct
region
polypeptide sequence
amino
terminus
Prior art date
Application number
LU90458C
Other languages
English (en)
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24914180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90458(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of LU90458I2 publication Critical patent/LU90458I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
LU90458C 1985-04-12 1999-10-12 Refacto LU90458I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72535085A 1985-04-12 1985-04-12

Publications (1)

Publication Number Publication Date
LU90458I2 true LU90458I2 (fr) 2001-04-13

Family

ID=24914180

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90458C LU90458I2 (fr) 1985-04-12 1999-10-12 Refacto

Country Status (12)

Country Link
US (1) US4868112A (fr)
EP (1) EP0218712B1 (fr)
JP (1) JPH0788399B2 (fr)
AT (1) ATE72838T1 (fr)
AU (2) AU5772886A (fr)
CA (1) CA1341174C (fr)
DE (1) DE3683980D1 (fr)
DK (1) DK166457B1 (fr)
ES (1) ES8801674A1 (fr)
LU (1) LU90458I2 (fr)
MX (1) MX9203440A (fr)
WO (1) WO1986006101A1 (fr)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (fr) * 1987-06-12 1996-09-11 Immuno Ag Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
KR960701899A (ko) * 1989-11-17 1996-03-28 안네 제케르 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US20060122376A1 (en) * 1991-02-07 2006-06-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
WO1993025712A1 (fr) * 1992-06-15 1993-12-23 The Regents Of The University Of California Test de triage pour l'identification de medicaments immunosuppresseurs
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
EP0710288B1 (fr) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Vecteurs adenoviraux pour le traitement de l'hemophilie
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (fr) * 1993-07-23 1995-02-02 Baxter International Inc. Facteur viii humain active et procede de preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
WO1997040145A1 (fr) * 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Facteur viii resistant a l'inactivation
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP1036177A1 (fr) * 1997-12-05 2000-09-20 The Immune Response Corporation Vecteurs et genes a expression accrue
ES2182501T3 (es) 1998-03-12 2003-03-01 Inst Genetics Llc Metodos mejorados para producir proteinas del factor viii.
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
NZ511034A (en) 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
US6517830B1 (en) * 1999-08-05 2003-02-11 Emory University Compositions and methods for the expression of factor VIII polypeptides and uses therefor
JP2005518181A (ja) * 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
ES2331909T3 (es) 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
EP1707634A1 (fr) 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
EP1739179A1 (fr) 2005-06-30 2007-01-03 Octapharma AG Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2656558A1 (fr) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Procede de production de proteines de type facteur viii par des procedes recombinants
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
BRPI0821591A2 (pt) 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
SG187397A1 (en) 2007-12-27 2013-02-28 Baxter Int Cell culture processes
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
DK2349341T3 (da) 2008-10-15 2014-01-06 Baxter Int Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
US8691211B2 (en) * 2009-03-10 2014-04-08 Puget Sound Blood Center Suppression of immune response to factor VIII in hemophilia A patients
CA2771999A1 (fr) 2009-08-24 2011-03-10 Amunix Operating Inc. Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci
EP2493921B1 (fr) 2009-10-30 2018-09-26 Albumedix Ltd Variants d'albumine
EP2498803A4 (fr) * 2009-11-13 2013-05-15 Puget Sound Blood Ct Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
WO2011095604A1 (fr) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Prolongation de la demi-vie de protéines
EP2556087A1 (fr) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Dérivés et variants d'albumine
EP3508573A1 (fr) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
WO2013016454A1 (fr) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Dosages pour la surveillance de troubles hémostatiques
JP6029674B2 (ja) 2011-10-18 2016-11-24 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
WO2013057167A1 (fr) 2011-10-18 2013-04-25 Csl Behring Gmbh Utilisation de glycosaminoglycanes sulfates pour ameliorer la biodisponibilite du facteur viii
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
WO2013185113A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Composés pro-coagulants
CA2875247A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Facteurs de coagulation chimeriques
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
WO2014127215A1 (fr) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Gène du facteur viii optimisé
EP4122487A1 (fr) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
WO2014144549A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Préparations contenant un polypeptide du facteur ix
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
WO2015021423A2 (fr) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification de molécules chimères du facteur viii
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (fr) 2013-09-08 2015-03-12 Oligasis Llc Conjugués polymère zwittérionique-facteur viii
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015120056A1 (fr) 2014-02-04 2015-08-13 Biogen Ma Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN104630131B (zh) * 2015-01-15 2017-08-15 上海交通大学 一种稳定表达人凝血八因子的cho细胞株及其应用
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
EP3167877A1 (fr) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Procédé de production de granules lyophilisés comprenant le facteur viii
CA3005565A1 (fr) 2015-11-13 2017-05-18 Baxalta Incorporated Vecteurs viraux codant pour des variants du facteur viii de recombinaison avec une expression augmentee pour la therapie genique de l'hemophilie a
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
CA3012695A1 (fr) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Genes du facteur viii optimises
WO2017222337A1 (fr) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
EP3687580A1 (fr) 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules actives
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
BR112020020084A2 (pt) 2018-04-04 2021-01-05 Sigilon Therapeutics, Inc. Partícula, preparação de uma pluralidade de partículas, método de preparação de uma partícula, e, composição de partículas.
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
EP3833766A1 (fr) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CN114007637A (zh) 2019-06-19 2022-02-01 比奥维拉迪维治疗股份有限公司 用于治疗血友病和低骨矿物质密度的重组因子viii-fc
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
WO2021119357A2 (fr) 2019-12-12 2021-06-17 Baxalta Incorporated Thérapie génique de l'hémophilie à l'aide de vecteurs viraux codant des variants de fviii recombinants présentant une expression accrue
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4355768A1 (fr) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
JP2025534667A (ja) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド 疾患治療のための改変細胞及び移植可能エレメント
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2025008774A1 (fr) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Vecteurs viraux codant pour des variants de fviii recombinants ayant une expression accrue pour la thérapie génique de l'hémophilie a

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399009I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill

Also Published As

Publication number Publication date
WO1986006101A1 (fr) 1986-10-23
JPH0788399B2 (ja) 1995-09-27
AU629649B2 (en) 1992-10-08
ATE72838T1 (de) 1992-03-15
ES8801674A1 (es) 1988-02-16
EP0218712A1 (fr) 1987-04-22
DK601786A (da) 1986-12-12
DE3683980D1 (de) 1992-04-02
AU5772886A (en) 1986-11-05
JPS62502941A (ja) 1987-11-26
US4868112A (en) 1989-09-19
CA1341174C (fr) 2001-01-30
DK601786D0 (da) 1986-12-12
ES553935A0 (es) 1988-02-16
DK166457B1 (da) 1993-05-24
MX9203440A (es) 1992-07-01
EP0218712A4 (fr) 1987-10-27
EP0218712B1 (fr) 1992-02-26
AU5753490A (en) 1991-02-07

Similar Documents

Publication Publication Date Title
LU90458I2 (fr) Refacto
ISEMURA et al. Isolation and amino acid sequence of SAP-1, an acidic protein of human whole saliva, and sequence homology with human γ-trace
NL300106I1 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
KR880701105A (ko) 신규 응혈촉진 단백질
CA2025598A1 (fr) Proteines d'antigene nucleocapsidique d'hepadnavirus chimerique
DK382786D0 (da) Overfladeaktivt rekombinant-alveolarprotein
ATE413189T1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
BR9506733A (pt) Proteina de fusão de hematopoiese il-3 multivarian
NZ333999A (en) GnRH-leukotoxin chimeric proteins for use in vaccines
ZA894721B (en) Leader sequence inducing a post-translational modification of polypeptides in bacteria,and gene therefor
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
EP0310887A3 (en) Vasoconstrictor peptide
EP0330700A4 (fr) Polypeptide ressemblant à la prourokinase humaine.
FI93843B (fi) Menetelmä angiogeenisen tekijän tuottamiseksi
ATE110389T1 (de) Thf-zusammensetzungen.
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
DE69121489D1 (de) In vitro-Behandlung von Fusionsproteinen
EP0723016A3 (fr) Facteur d'activation des leukocytes
CA2004764A1 (fr) Proteines ancrod, leur preparation et leur utilisation
IL95890A0 (en) Hiv related peptides
方军 et al. Observation on the specific binding site of p195 protein on human erythrocytes using colloidal gold labelling
DK53290A (da) Syntetiske gaer-leader-peptider